Elexopharm Gmbh

Merck Sharp + Dohme Corp.

Aero Pump Gmbh

Universität Des Saarlandes

Ralf Heim

Rolf Wolfgang Hartmann

Amjad Ali

Michael Man-Chu Lo

Lina Yin

Qingzhong Hu

Simon Lucas

Edward Metzger

Christina Zimmer

Yusheng Xiong

Timothy J Henderson

Bheemashankar A Kulkarni

Clare London

Scott B Hoyt

Jerry Andrew Taylor

Swapan Kumar Samanta

Rohit Saxena

Andreas Mersmann

Emmanuel Bey

Whitney Lane Petrilli

Bey; Emmanuel

Michael Lo

Childproof safety cap has two opposite bead-like threads on its inner wall. Each thread has a widened end region, a stop surface thus being formed. The associated bottle has two opposite groove-like threads on a connecting piece of the bottle, each of which threads has a widened region in the end region, an undercut thus being formed in the groove by the widened region. When the safety cap is screwed on, the stop surfaces on the two bead-like threads hook in behind the undercuts on the groove-like threads. The stop surfaces can be released from each other only if the safety cap is pressed down toward the bottle onto the connecting-piece neck. Connecting-piece neck forms a slipping surface that conically expands downwards. The safety cap can then be unscrewed while simultaneously being rotated.

Childproof safety cap and associated container for liquid or pasty substances

This invention relates to indoline compounds of the structural formula: or their pharmaceutically acceptable salts, wherein the variables are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase.

Indoline compounds as aldosterone synthase inhibitors

This invention relates to indo line compounds of the structural formula I, or their pharmaceutically acceptable salts, wherein the variables are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase. 

This invention relates to tricyclic triazole analogs of the formula I or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthetase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthetase. 

Aldosterone synthase inhibitors

The invention provides compounds of the general formula (I) which are inhibitors of the human aldosterone synthase, and also pharmaceutical compositions containing these compounds, and the use of these compounds and other heteroaryl substituted quinolinone derivatives for the treatment of hyperaldosteronism and/or disorders or diseases that are mediated by 11 &#x3b2;-hydroxylase (CYP11 B1). 

6-pyridin-3-yl-3,4-dihydro-1h-quinolin-2-one derivatives and related compounds as inhibitors of the human aldosterone synthase CYP11B2

The invention provides compounds of the general formula (I) which are inhibitors of the human aldosterone synthase, and also pharmaceutical compositions containing these compounds, and a method of treating of hyperaldosteronism and/or disorders or diseases that are mediated by 11&#x3b2;-hydroxylase (CYP11B1) with these compounds.

Inhibitors of the human aldosterone synthase CYP11B2

Growing community of inventors

Wiesbaden, Germany

Ralf Heim